Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | PPM1D | O15297 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25819727 | 0.90 | PARP10 (0.41) | PARP10PARP15SLC2A1THRATHRB | |
| SCHEMBL29818738 | 0.89 | PARP10 (0.44) | PARP10PARP15SLC2A1THRATHRB | |
| SCHEMBL2204386 | 0.89 | PARP10 (0.44) | PARP10PARP15SLC2A1THRATHRB | |
| SCHEMBL4568839 | 0.88 | PARP15 (0.42) | PARP10PARP15SLC2A1THRATHRB | |
| SCHEMBL25819702 | 0.77 | KMT2A (0.44) | SLC2A1 | |
| SCHEMBL2208665 | 0.76 | KMT2A (0.37) | PARP10PARP15THRATHRBF2 | |
| SCHEMBL10068795 | 0.76 | WDR5 (0.44) | PARP10PARP15PARP2F2ADORA2B | |
| SCHEMBL17934005 | 0.76 | CA12 (0.51) | PARP10PARP15PARP2F2ADAM17 | |
| SCHEMBL10068809 | 0.75 | PARP15 (0.49) | PARP10PARP15PARP2F2 | |
| SCHEMBL21819200 | 0.75 | WDR5 (0.43) | PARP10PARP15PARP2F2ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | PARP10 1846/4885PARP15 2575/4885SLC2A1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.